Press release
Chemotherapy-Induced Peripheral Neuropathy Market Size, Share and Growth Report, 2034
Chemotherapy-Induced Peripheral Neuropathy Market
Chemotherapy-Induced Peripheral Neuropathy (CIPN) has emerged as one of the most challenging complications for cancer patients undergoing chemotherapy. As cancer treatment regimens improve survival rates, the quality of life during and after therapy has become a major focus for oncologists and healthcare providers. CIPN, characterized by pain, numbness, tingling, and functional impairment in the extremities, affects up to 68% of patients receiving neurotoxic chemotherapy drugs. The global market for CIPN treatments and management solutions is gaining significant traction as pharmaceutical innovation, improved diagnostics, and patient-centered care converge to address this unmet need.
The CIPN market, which stood at USD 1.75 billion in 2024, is projected to reach USD 3.62 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.6% during the forecast period. This growth is underpinned by an increasing global cancer incidence, expansion of oncology drug pipelines, and rising adoption of supportive care protocols.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/reports/59107/global-intratumoral-cancer-therapies-market#request-a-sample
Market Overview: Key Highlights
• Market Size 2024: USD 1.75 billion
• Forecast 2034: USD 3.62 billion
• CAGR (2024-2034): 7.6%
• Major Drivers: Rising cancer prevalence, oncology R&D investment, adoption of patient quality-of-life standards.
• Key Challenges: Lack of universally effective therapies, limited awareness in low-income regions, regulatory approval delays.
• Leading Players: Novartis AG, Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, GlaxoSmithKline plc, NeuroMetrix Inc., Biohaven Pharmaceuticals, PledPharma AB, Astellas Pharma Inc.
Segmentation Analysis
By Drug Type
• Antidepressants (e.g., duloxetine, amitriptyline)
• Anticonvulsants (e.g., gabapentin, pregabalin)
• Opioids & Non-opioid Analgesics
• Topical Agents (lidocaine, capsaicin)
• Nutritional Supplements & Neuroprotective Agents
By Chemotherapy Agent Causing CIPN
• Platinum-based drugs (cisplatin, oxaliplatin)
• Taxanes (paclitaxel, docetaxel)
• Vinca alkaloids (vincristine, vinblastine)
• Bortezomib and other proteasome inhibitors
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End User
• Hospitals & Oncology Clinics
• Ambulatory Care Centers
• Homecare Settings
Segmentation Summary:
The antidepressant segment currently leads due to strong clinical evidence supporting duloxetine as the only drug with significant guideline-based recommendations for CIPN management. However, the nutraceutical and neuroprotective segment is expected to grow rapidly as research into oxidative stress modulation gains momentum.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=59107
Regional Analysis
North America
• Largest market share (~38% in 2024) due to advanced oncology infrastructure and high adoption of guideline-based CIPN management.
• Robust pipeline of neuroprotective drugs and high awareness levels among oncologists.
Europe
• Strong presence of supportive oncology care programs, especially in Germany, France, and the UK.
• Stringent reimbursement policies but increasing inclusion of CIPN management in cancer care protocols.
Asia-Pacific
• Fastest-growing region with a CAGR of over 9% due to rising cancer incidence in China, India, and Japan.
• Increasing government healthcare investments and expanding oncology drug access.
Middle East & Africa
• Market growth driven by expanding cancer treatment centers in GCC countries.
• Limited awareness and access in sub-Saharan Africa remain challenges.
Latin America
• Brazil and Mexico lead adoption due to improving cancer screening and treatment programs.
• Growth potential as regional pharmaceutical players enter supportive oncology care.
Regional Summary:
North America dominates the market, but Asia-Pacific presents the most lucrative growth opportunities, driven by large patient pools and rapid healthcare modernization.
Market Dynamics
Key Growth Drivers
1. Rising Cancer Incidence: WHO data projects over 30 million new cancer cases annually by 2040, driving chemotherapy usage.
2. Pharmaceutical Innovation: Development of novel neuroprotective agents and repurposing of existing drugs.
3. Clinical Guideline Integration: Inclusion of CIPN management in oncology care pathways boosts adoption rates.
4. Growing Patient Awareness: Demand for quality-of-life interventions post-chemotherapy.
Key Challenges
• Lack of curative treatment for CIPN-current therapies are mostly symptomatic.
• Limited physician training in CIPN recognition in low- and middle-income countries.
• Difficulty in conducting large-scale CIPN clinical trials due to variability in onset and severity.
Latest Trends
• Use of wearable neurostimulation devices for pain management.
• Advancements in biomarker-based prediction of CIPN risk.
• Increasing focus on combination therapies (drug + non-drug interventions).
• Telehealth expansion for CIPN symptom monitoring and medication adjustments.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/59107/global-intratumoral-cancer-therapies-market
Competitor Analysis
Major Players
• Novartis AG
• Pfizer Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• NeuroMetrix Inc.
• Biohaven Pharmaceuticals
• PledPharma AB
• Astellas Pharma Inc.
• Kyowa Kirin Co., Ltd.
• Cipla Ltd.
• Mylan N.V.
• Sorrento Therapeutics, Inc.
• Aptinyx Inc.
Competitive Summary:
The market is moderately consolidated, with large pharma companies focusing on expanding their supportive care portfolios through both new drug development and acquisitions. Start-ups and mid-sized firms are innovating in device-based CIPN therapies, creating a hybrid drug-device competitive landscape.
Conclusion: Outlook and Opportunities
The Chemotherapy-Induced Peripheral Neuropathy market is on a strong growth trajectory through 2034, fueled by the dual push of increasing cancer prevalence and the urgent need for quality-of-life interventions. While no definitive cure exists, the accelerating pace of research into both pharmaceutical and device-based solutions offers hope for more effective, patient-friendly options.
This report is also available in the following languages : Japanese (腫瘍内癌治療市場), Korean (종양 내 암 치료 시장), Chinese (肿瘤内癌症治疗市场), French (Marché des thérapies intratumorales contre le cancer), German (Markt für intratumorale Krebstherapien), and Italian (Mercato delle terapie contro il cancro intratumorale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/59107/global-intratumoral-cancer-therapies-market
Our More Report:
Sports Compression Wear Market
https://exactitudeconsultancy.com/request-sample/65104
Plastic Additives Market
https://exactitudeconsultancy.com/request-sample/65106
Paper Bags Market
https://exactitudeconsultancy.com/request-sample/65108
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy-Induced Peripheral Neuropathy Market Size, Share and Growth Report, 2034 here
News-ID: 4138353 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for CIPN
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Growing Focus and Marke …
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment, caused by damage to peripheral nerves from drugs such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. CIPN manifests as pain, numbness, tingling, and motor dysfunction, often leading to dose reduction or discontinuation of chemotherapy, which can compromise cancer outcomes.
With up to 68% of patients developing CIPN during chemotherapy, this condition represents a significant unmet…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline 2025: Groundbreaking …
With Chemotherapy Induced Peripheral Neuropathy (CIPN) reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Chemotherapy Induced Peripheral Neuropathy (CIPN). These therapies span various stages of clinical and…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market 2034: Clinica …
Chemotherapy Induced Peripheral Neuropathy companies working in the market are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Set to Experience Unpre …
DelveInsight's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Chemotherapy-Induced Peripheral Neuropathy (CIPN), historical and forecasted epidemiology as well as the Chemotherapy-Induced Peripheral Neuropathy (CIPN) market trends in the India, China, South Korea, Taiwan, and Australia.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Analysis Covering Cli …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy Induced Peripheral Neuropathy…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis (2023) Cover …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy-Induced Peripheral Neuropathy (CIPN)…
